Trial Profile
Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC 736511, IND 74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jul 2022
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2017 Results published in the Journal of Thoracic Oncology
- 26 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.